

Recommending MCV4 for persons 11-18 years old

**Advisory Committee on Immunization Practices
June 27, 2007**

Amanda Cohn, MD
Meningitis and Vaccine Preventable Diseases Branch
National Center for Immunization and Respiratory
Diseases
Centers for Disease Control and Prevention

Draft Notice to Readers, June 2007

- May 2005 ACIP recommendation for MCV4
- Revised ACIP recommendation
- Implementation discussion
- Recommendations for persons with a history of Guillian-Barre Syndrome (GBS)

Current ACIP Recommendation for MCV4

- Routine vaccination of the following groups:
 - Persons aged 11-12 years
 - Adolescents at high school entry (i.e., at approximately age 15 years)
 - Other persons at increased risk of meningococcal disease

Factors Influencing 2005 Recommendation

- Routine vaccination of 11-12 year olds emphasizes the ACIP-recommended routine health care visit at 11-12 years
- Target increasing risk in late adolescence
- Implementation of adolescent recommendations for MCV4 might be affected by short-term supply limitations

Rationale for Change

- “Simplified recommendations for use of MCV4 could improve coverage.”
- “Current and future MCV4 supply is expected to be sufficient to meet increased vaccine uptake resulting from simplified recommendations.”

Revised ACIP MCV4 Recommendation

- “ACIP recommends vaccination with one dose of MCV4 of all 11-18 year olds.
- Persons 11-12 years old should be routinely vaccinated at the ACIP recommended 11-12 year old health care visit”*

*CDC. Immunization of Adolescents Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR 1996;45(RR-13):1-16.

Revised ACIP MCV4 Recommendation

- “Routine vaccination also is recommended for persons who are at increased risk for meningococcal disease, including
 - College freshmen living in dorms
 - Military recruits
 - Microbiologists routinely exposed to isolates of *N. meningitidis*
 - Travelers to or residents of countries in which *N. meningitidis* is hyperendemic or epidemic
 - Persons with terminal complement component deficiencies
 - Persons with anatomic or functional asplenia.”

Implementation

- Emphasis of 11-12 year old recommended health care visit
- Implementation of recommendation for college freshmen living in dorms
- Timing of vaccination

Emphasis of 11-12 year old Health Care Visit

- “The ACIP goal is routine vaccination of all adolescents beginning at age 11 years.
- ACIP and partner organizations, including the American Academy of Pediatrics, American Academy of Family Physicians, American Medical Association and Society for Adolescent Medicine, recommend a health-care visit for 11-12 year olds to receive appropriate immunizations and other evidence-based preventive services.”

Emphasis of 11-12 year old Health Care Visit

- “A recommendation for MCV4 vaccination among persons aged 11-12 years could strengthen the role of this preventive care visit and have a positive effect on vaccine coverage of all recommended adolescent vaccines.”

Recommendations for College Freshmen

- “College freshmen living in dormitories are at increased risk of meningococcal disease and should be vaccinated with MCV4 before college entry, if not previously.
- Because of feasibility constraints in targeting freshmen in dormitories, colleges may elect to target their vaccination campaigns to all matriculating freshmen.”

Timing of Vaccination

- “Because the incidence of meningococcal disease increases during adolescence, health care providers should take the opportunity to vaccinate previously unvaccinated 11-18 year-olds with MCV4 at the earliest possible health care visit.
- ACIP encourages health care providers to vaccinate with MCV4 throughout the year to minimize seasonal increases in demand associated with “back to school” months.
- Providers may want to consider VFC eligibility lapses after age 18 years when making decisions about timing of vaccination”

Recommendations for persons with a history of GBS

- “Because of a reported association of Guillain-Barre syndrome (GBS) after receipt of MCV4, persons with a history of GBS may be at increased risk and should discuss their risk of meningococcal disease with their healthcare provider when deciding whether or not to be vaccinated.”*

*CDC. Update: Guillain-Barre syndrome among recipients of Menactra® meningococcal conjugate vaccine—United States, June 2005-September 2006. MMWR 2006;55:1120-1124.

Conclusions

- The meningococcal ACIP Working Group anticipates that these recommendations will have the following benefits:
 - simplify provider decisions to vaccinate
 - improve adolescent coverage

Discussion

Vote

- “ACIP recommends vaccination with one dose of MCV4 of all 11-18 year olds.
- Persons 11-12 years old should be routinely vaccinated at the ACIP recommended 11-12 year old health care visit
- Routine vaccination also is recommended for persons who are at increased risk for meningococcal disease...”